Anhui Fengyuan Pharmaceutical Co., Ltd.

The transfer of controlling stake to Bengbu Investment Group, a state-owned entity under SASAC of Bengbu Municipality, could bring greater financial stability, government backing, and access to state resources, potentially strengthening Fengyuan Pharmaceutical's long-term strategic positioning and creditworthiness.

The ownership change introduces significant uncertainty around governance, strategic direction, and execution. The transaction is priced at a premium over market value, raising concerns about capital allocation discipline, while regulatory approval from state-owned asset authorities adds further timing and outcome risk.

Despite consecutive revenue declines, Fengyuan Pharmaceutical maintains a diversified product portfolio spanning biologics, chemical drugs, traditional Chinese medicines, and pharmaceutical distribution, which may provide a foundation for recovery once market conditions stabilize and strategic restructuring under new ownership takes effect.

The company's 2025 annual report revealed revenue down 9.95% and net profit down 38.19% year-over-year, with a Q4 net loss. The deterioration continued into Q1 2026 with revenue falling 11.14%, suggesting a deepening structural decline rather than a temporary cyclical downturn.

The share transfer agreement, based on an enterprise valuation of RMB 29.8 billion — implying a meaningful premium over the prevailing market capitalization of RMB 24.30 billion — signals that Bengbu Investment Group views Fengyuan Pharmaceutical as strategically undervalued, potentially catalyzing a market rerating.

The indicative transaction valuation of RMB 29.8 billion sits well above the current market cap of RMB 24.30 billion, raising concerns about overpayment and whether the premium is justified given the company's worsening financials, negative earnings momentum, and uncertain recovery timeline.